Home
overview

This conference has already taken place.  For information on the 2010 event, please click on the link below:

 

COPD: Novel Therapeutics and Management Strategies 2010

 


For information about the 2010 Asthma & COPD conference, please see below...

 

Products developed to treat the symptoms of Asthma and COPD provide one of the highest sources of revenue for the pharmaceutical industry. SMi’s 6th annual Asthma & COPD conference will present attendees with an exceptional line-up of speakers and an unrivalled forum for discussion and debate.

There will be an opportunity to hear about new research involving the use of bronchodilators and kinase-inhibitors as well as antibody based biologics. Presentations will also cover topics such as new therapeutic targets in asthma and COPD and optimising respiratory clinical trial data.

 

  • Hear about novel endpoints in COPD clinical trials
  • Explore the application of in vitro cell models in drug development
  • Learn about the use of the use of protein kinases as drug targets
  • Discuss methods for candidate drug selection and risk management
  • Network with industry associates and share experiences
 

 

Managers, Directors and Senior Scientists working at pharmaceutical or biotech organisations in the following areas:

 

                              
  • Respiratory Science
  • Research & Development
  • Inflammation & Inhalation
  • Clinical & Regulatory Affairs
  • Drug Discovery
  • Respiratory Illness
 
   
  • Inhalation Drug Delivery
  • Project Management
  • Preclinical Development
  • Portfolio Management
  • Marketing
  • Drug Delivery
 

 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Peter Barnes

Peter Barnes, Head of Respiratory Medicine, Imperial College London

9:10 KEYNOTE ADDRESS

Peter Barnes

Peter Barnes, Head of Respiratory Medicine, Imperial College London

  • Discuss progress in understanding asthma and COPD
  • Similarities between COPD and severe asthma
  • Developing biomarkers to aid drug development
  • What are the unmet needs?
  • 9:50 IMPACT OF DRUG SUBSTANCE AND PRODUCT CHARACTERISTICS ON IN-VITRO PERFORMANCE

    Frank Thielmann

    Frank Thielmann, PDU Manager, Novartis

  • Parameters affecting in-vitro and in-vivo performance
  • Parameters affecting stability
  • How can these parameters be measured?
  • Monitoring and control of parameters during development
  • 10:30 Morning Coffee

    10:50 TARGETING INFLAMMATION IN COPD

    Dave Singh

    Dave Singh, Medical Director, Medicines Evaluation Unit, University Hospital Of South Manchester NHS Foundation Trust

  • Lung cell models
  • Corticosteroid Insensitivity
  • Novel Targets
  • Clinical Trial Data
  • 11:30 NOVEL AND EMERGING BRONCHODILATORS

    Alan Young

    Alan Young, Associate Director and Principal Scientist, AstraZeneca

  • Role of bronchodilators in the treatment of asthma and COPD
  • The need for long- acting bronchodilators
  • Evidence from in vitro studies
  • Emerging trends
  • 12:10 Networking Lunch

    13:10 ANTIBODY BASED BIOLOGICS FOR THE TREATMENT OF ASTHMA

    Matthew Catley

    Matthew Catley, Head of Respiratory Pharmacology, UCB

  • Areas for antibody based biologics to make an impact in the clinic
  • Review of pre-clinical and clinical data
  • Patient stratification
  • Future directions for biologicals in asthma
  • 13:50 DEVELOPING THE PRE-CLINICAL PLATFORM OF EVIDENCE FOR COPD

    Thomas Eichholtz

    Thomas Eichholtz, Director of Discovery Medicine, AstraZeneca

  • Potential preclinical experiments
  • Outcomes and biomarkers
  • Link to human disease
  • Closing the translational loop
  • 14:30 Afternoon Tea

    14:50 EARLY PHARMACEUTICAL DEVELOPMENT: MAXIMISING PORTFOLIO DYNAMICS IN ASTHMA AND COPD

    Julien Giovanni

    Julien Giovanni, Team Manager Early Development, AstraZeneca

  • Understanding diversity of portfolio in early phase and CMC implications
  • Oral and inhalation key triggers for pharmaceutical development from lead optimisation to FIM/proof of principles
  • Candidate drug selection, ability to develop and risk management,
  • Example of properties evaluation from small molecules to oligonucleotides
  • 15:30 PHASE 2 PROOF OF CONCEPT STUDIES FOR ASTHMA : WHAT ARE THE OPTIONS?

    Michael Hodges

    Michael Hodges, Chief Medical Officer, Altair Therapeutics

  • Bronchoprovocation and other challenges/mechanistic type studies
  • Clinical asthma POC studies
  • Which design is best? Strategic, logistical and sample size considerations
  • 16:50 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration & Coffee

    9:00 Chairman's Opening Remarks

    Peter Howarth

    Peter Howarth, Reader in Medicine and Head of Clinical Translational Research, University Of Southampton School Of Medicine

    9:10 EMERGING AREAS IN AIRWAYS DISEASE

    Peter Howarth

    Peter Howarth, Reader in Medicine and Head of Clinical Translational Research, University Of Southampton School Of Medicine

  • Respiratory microbiome
  • Biomechanical forces
  • Structural influences
  • Small airways
  • 9:50 HUMAN IN VITRO MODELS AS TRANSLATIONAL RESEARCH TOOLS

    Phillip Monk

    Phillip Monk, Chief Scientific Officer, Synairgen

  • The need to improve the ability of preclinical models to predict clinical outcome
  • Focus on models of mechanisms relevant to asthma and COPD
  • Examples of use of models for both target identification and target validation
  • Sourcing tissue and cells from subjects with lung diseases
  • 10:30 Morning Coffee

    11:00 LESSONS LEARNED IN CENTRALISED SPIROMETRY

  • Over reading systems the plus and minuses
  • Identifying abnormalities and their cause
  • Catching errors before they become issues
  • Case studies
  • Aleck Harrison

    Aleck Harrison, Consultant Clinical Scientist, AJH Partners

    Grant Sowman

    Grant Sowman, Pulmonary Function Testing Specialist, Vitalograph

    11:40 PUTTING PHOSPHORYLATION IN THE FRAME: KINASES AS TARGETS FOR NEW THERAPIES

    Gordon Dent

    Gordon Dent , Senior Lecturer in Pharmacology, School of Medicine, Keele University

  • Signalling roles of protein and lipid kinases
  • Identification of kinase isoforms
  • Kinases as potential drug targets
  • Kinase inhibition as an approach to suppression of airway inflammation and remodelling
  • 12:20 Networking Lunch

    13:30 OLIGONUCLEOTIDES: NEW THERAPEUTIC APPROACHES FOR ASTHMA AND COPD

    Mark Parry-Billings

    Mark Parry-Billings, Chief Executive Officer, Topigen Pharmaceuticals

  • Overview of the therapeutic class
  • Developments in targeting lung disease
  • Pre-clinical development : challenges and attributes
  • Emerging clinical data and product profiles
  • 14:10 DOSING AND TARGETING STRATEGIES FOR PULMONARY CLINICAL TRIALS

    Thomas Hofmann

    Thomas Hofmann, Chief Medical Officer, Activaero

  • Parameters influencing lung dose of inhaled drugs
  • Options to improve consistency in lung dose
  • Potential to improve quality of trial outcomes by controlled inhalation
  • Regulatory and commercial aspects of device selection during different development stages
  • 14:50 DNAZYM TECHNOLOGY FOR ASTHMA TREATMENT

    Harald Renz

    Harald Renz, Professor and Chairman, Department of Clinical Chemistry and Molecular Diagnostics - Central Laboratory, University Of Marburg

  • DNAzyme technology
  • Possible targets suitable for DNAzym approach
  • Off-target effects
  • Preclinical considerations
  • 15:30 Close of Conference and Afternoon Tea

    +

    Workshops

    Device Possibilities for Future Inhaled Therapies
    Workshop

    Device Possibilities for Future Inhaled Therapies

    Marriott Hotel Regents Park
    20th April 2010
    London, United Kingdom

    Marriott Hotel Regents Park

    128 King Henry’s Road
    London NW3 3ST
    United Kingdom

    Marriott Hotel Regents Park

    This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.